Radium-223 Dichloride in the treatment of patients diagnosed with prostate cancer that has spread to the bone

• Conditions: Castrate Resistant Prostate Cancer/Hormone-Refractory Prostate Cancer patients with bone metastasis; MedDRA version: 14.1Level: LLTClassification code 10036916Term: Prostate cancer stage DSystem Organ Class: 100000004864; Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2012-000075-16-FI
• Lead Sponsor: Bayer HealthCare AG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-04-30
• Last Update Posted: 7 April 2015

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: Male
• Target Recruitment: 1500

Inclusion Criteria

Eligible patients will conform to all of the inclusion criteria listed below:
•Has provided written informed consent. Subjects must be able to understand and be willing to sign the written informed consent form (ICF). A signed ICF must be appropriately obtained prior to the conduct of the any trial- specific procedure.
•Age =18 years
•Histologically or cytologically confirmed prostate cancer
•Patients diagnosed with progressive bone predominant metastatic CRPC/HRPC with at least two skeletal metastases on imaging with no lung, liver, and/or brain metastasis (lymph node only metastasis is allowed). A standard of practice bone scan for the documentation of at least 2 skeletal metastases can be used as long as it is within 3 months of planned start of treatment. If no bone scan within a 3 month window is available, then a technetium-99m bone scan will be obtained at screening (within 28 days of planned start of study drug)
•Progressive disease is defined either by:
oThe appearance of new bone lesions. If progression is based on new lesion(s) on bone scan only without an increase in prostate specific antigen (PSA), PSA values from 3 assessments within the last 6 months must be provided; OR
oIn the absence of new bone lesions by 2 subsequent increases in serum PSA over previous reference value, which should not be more than 6 months before screening, each measured at least 1 week apart with the last PSA = 5 ng/mL. (The reference value time point 1, is defined as the last PSA measured before increases are documented, with subsequent values obtained a minimum of 1 week apart. If the PSA at time point 3 is greater than the PSA at time point 2, then eligibility has been met. If the PSA at time point 3 is not greater than the PSA at time point 2 but the PSA value at time point 4 and/or time point 5 is greater than the PSA at time point 2, the patient is eligible assuming that other criteria are met)
•No intention to use cytotoxic chemotherapy within the next 6 months
•Life expectancy = 6 months
•Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2
•Adequate hematological, liver, and renal function
oAbsolute neutrophil count (ANC) = 1.5 x10 9/L
oPlatelet count = 100 x10 9/L
oHemoglobin =10.0 g/dL (100 g/L; 6.2 mmol/L)
oTotal bilirubin level = 1.5 x institutional upper limit of normal (ULN)
oAspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5 x ULN
oCreatinine = 1.5 x ULN
oAlbumin > 25 g/L
•Willing and able to comply with the protocol, including follow-up visits and examinations
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 675
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 675

Exclusion Criteria

Eligible patients must not meet any of the exclusion criteria listed below
•Treatment with an investigational drug within previous 4 weeks, or planned during the treatment period or follow-up
•Eligible for first course of docetaxel, i.e., patients who are fit enough, willing, and who are located where treatment with docetaxel is available
•Treatment with cytotoxic chemotherapy within previous 4 weeks, prior to screening, or failure to recover from AEs due to cytotoxic chemotherapy administered more than 4 weeks previous prior to screening (however, ongoing neuropathy is permitted)
•Treatment with any prior anticancer therapy (including, therapeutic vaccines), other than the permitted Standard of Care therapies (please refer to section 6.9), are allowed provided that they are completed 28 days before treatment or 5.5 half-lives of the drugs involved have elapsed before treatment start.
•Prior hemibody external radiotherapy is excluded. Patients who received other types of prior external radiotherapy are allowed provided that the bone marrow function is assessed and meets the protocol requirements for hemoglobin, absolute neutrophil count and platelets.
•Received systemic therapy with radionuclides (e.g., strontium-89, samarium-153, rhenium-186, or rhenium-188, or radium-223 dichloride) for the treatment of bony metastases
•Other malignancy treated within the last 3 years (except non melanoma skin cancer or low-grade superficial bladder cancer)
•Visceral metastases as assessed by abdominal or pelvic computed tomography (CT) (or other imaging modality based on institutional standard of care)
•Presence of brain metastases
•Lymphadenopathy exceeding 6 cm in short-axis diameter
•Any size pelvic lymphadenopathy if it is thought to be a contributor to concurrent hydronephrosis.
•Imminent spinal cord compression based on clinical findings and/or magnetic resonance imaging (MRI). Patients with history of spinal cord compression should have completely recovered.
•Any other serious illness or medical condition, such as but not limited to:
oAny infection = National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 Grade 2
oCardiac Failure New York Heart Association (NYHA) Class III or IV
oCrohn’s disease or ulcerative colitis
oBone marrow dysplasia
•Fecal incontinence

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified